Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 12 11 2019
accepted: 17 03 2020
pubmed: 24 6 2020
medline: 11 2 2021
entrez: 24 6 2020
Statut: ppublish

Résumé

Growth arrest-specific 6 (Gas6) and its receptors have been shown to play a crucial role in the homeostasis of the innate immune system by regulating apoptosis and inflammation. We aimed to verify whether an impairment of this system is associated with systemic lupus erythematosus (SLE) disease activity and with lupus nephritis (LN). Plasma Gas6 and the soluble cleaved form of the receptors MerTK (sMer) and Axl (sAxl) concentrations were measured in n=59 SLE patients (n=44 with nephritis, 75%) and analysed in relationship to clinical and laboratory data. Patients with LN were characterised by higher Gas6 (19.0 ng/mL [16.8-24.5] vs. 16.5 ng/mL [13.89-18.91]; p=0.03) and sAxl plasma levels than those without LN (31.36 ng/mL [25.1-41.4] vs. 20.2 ng/mL [15.6-30.7]; p=0.03); conversely sMer plasma concentrations were similar between groups. All the three biomarkers studied were directly correlated to creatinine and daily proteinuria, being inversely related to creatinine clearance. 39 patients had a proteinuria level of <0.5 mg/day, 14 between 0.5 and 3.5 mg/day and 5 had ≥3.5 g/day; Gas6, sAxl and sMer plasma concentrations significantly increased for increasing degree of proteinuria (test for trend p=0.0002; p=0.02; p=0.009, respectively).These correlations were confirmed in multiple linear regression analysis models accounting for gender, age, disease duration and concomitant treatment. Plasma Gas6, sAxl and sMer concentrations are associated with the severity of LN in patients affected by SLE. The excess cleavage of TAM receptors might contribute to LN pathogenesis.

Identifiants

pubmed: 32573415
pii: 14373
doi: 10.55563/clinexprheumatol/xyylza
doi:

Substances chimiques

Biomarkers 0
Intercellular Signaling Peptides and Proteins 0
Proto-Oncogene Proteins 0
Receptor Protein-Tyrosine Kinases EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

132-138

Subventions

Organisme : Versus Arthritis
ID : 21890
Pays : United Kingdom

Auteurs

Mattia Bellan (M)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; Internal Medicine Division, Maggiore della Carità Hospital, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy. bellanmattia@yahoo.it.

Marco Quaglia (M)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara; and Division of Nephrology and Renal Transplantation, Maggiore della Carità Hospital, Novara, Italy.

Alessandra Nerviani (A)

Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, UK.

Daniele Mauro (D)

Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, UK.

Myles Lewis (M)

Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, UK.

Federica Goegan (F)

Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Antonello Gibbin (A)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Internal Medicine Division, Maggiore della Carità Hospital, Novara, Italy.

Sara Pagani (S)

Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Livia Salmi (L)

Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Luca Molinari (L)

Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.

Luigi Mario Castello (LM)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Emergency Medicine Department, Maggiore della Carità Hospital, Novara, Italy.

Gian Carlo Avanzi (GC)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Emergency Medicine Department, Maggiore della Carità Hospital, Novara, Italy.

Vincenzo Cantaluppi (V)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara; and Division of Nephrology and Renal Transplantation, Maggiore della Carità Hospital, Novara, Italy.

Mario Pirisi (M)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Internal Medicine Division, Maggiore della Carità Hospital, Novara, Italy.

Pier Paolo Sainaghi (PP)

Department of Translational Medicine, Università del Piemonte Orientale, Novara; Internal Medicine Division, Maggiore della Carità Hospital, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.

Costantino Pitzalis (C)

Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH